Although the implication of IL-6 has tended to be on proinflammatory signaling activation, recent studies suggested a dual role in the homeostatic control of metabolism, for instance, mice lacking Il6 gene develop insulin resistance and liver inflammation, while patients receiving IL-6R blocking drug therapy increased body weight and developed dyslipidemia [34]. The gene discussed is IL6R; the disease is metabolic syndrome.